AMRP functions as an NRF2 inhibitor, potentially reducing tumor progression through modulation of the PTEN/PI3K/AKT signaling pathway and inhibition of proto-oncogenes, thereby promoting degradation of hypoxia-inducible factor-1α. The gene discussed is PTEN; the disease is neoplasm.